Anthropic launched Claude for Life Sciences, a purpose‑built large language model with integrations for scientific workflows and partnerships with 10x Genomics and Benchling to interrogate single‑cell and experimental datasets. The company framed the offering as an enterprise tool to accelerate data analysis and hypothesis generation in life sciences. Genomics unveiled Mystra, an AI human‑genetics platform designed to convert large genotype‑phenotype datasets into actionable target insights for drug discovery and validation. Genomics emphasizes that genetics‑backed targets have higher probabilities of clinical success and positions Mystra to support target selection and trial design. Both launches signal continued industry investment in AI tools tailored to biotech R&D. Drug developers should evaluate these platforms for integration into target‑validation pipelines, reproducibility, data provenance and regulatory traceability.